Research Topics
Genomes and Genes
Species | Madeleine DuvicSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Photopheresis versus transimmunization?Madeleine Duvic
MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
Leuk Lymphoma 47:1449. 2006
Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey studyNiyati Mukherjee
Department of Internal Medicine, University of North Carolina Hospitals, Chapel Hill, USA
BMC Dermatol 9:11. 2009..The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA...
Optimizing denileukin diftitox (Ontak) therapyMadeleine Duvic
The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, Department of Dermatology, 1515 Holcombe Blvd, Unit 1452, Houston, TX 77030, USA
Future Oncol 4:457-69. 2008....
CD30+ Neoplasms of the SkinMadeleine Duvic
Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA
Curr Hematol Malig Rep 6:245-50. 2011..The development of targeted therapy for CD30+ CTCLs will help in understanding the importance of the CD30 death receptor in pathogenesis and will improve treatment options...
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Madeleine Duvic
Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 434, Houston, TX 77030 4409, USA
Blood 109:31-9. 2007..Vorinostat demonstrated activity in heavily pretreated patients with CTCL. The 400 mg daily regimen had the most favorable safety profile and is being further evaluated...
Mycosis fungoides: pathophysiology and emerging therapiesMadeleine Duvic
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Semin Oncol 34:S21-8. 2007..The emergence of novel targeted therapies such as biologic agents, histone deacetylase inhibitors, and purine nucleoside phosphorylase inhibitors offers promise for more effective and safer treatment strategies for refractory CTCLs...
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene applicationMadeleine Duvic
Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 121:902-9. 2003..This association suggests that reversal of TIG-3 expression may help to explain the mechanism of retinoid action in epidermal differentiation and chemoprevention...
Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)Madeleine Duvic
Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma 2:222-8. 2002..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
Alopecia areata registry: an overviewMadeleine Duvic
Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Investig Dermatol Symp Proc 8:219-21. 2003..org. Samples of DNA, lymphoblast lines, and sera, as well as epidemiology and quality-of-life data, are being collected from well-characterized individuals, multiplex families, and sib pairs for future research studies and investigators...
Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphomaMadeleine Duvic
Department of Dermatology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
J Cutan Med Surg 7:3-7. 2003
Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entityM Duvic
Section of Dermatology, Division of Internal Medicine Specialties, M D Anderson Cancer Center, Houston, TX 77005, USA
Clin Lymphoma 1:141-5. 2000..Enterococcal infections in CTCL tumors may be recognized as a distinct clinical entity requiring specific intervention...
Treatment of cutaneous T-cell lymphoma from a dermatologist's perspectiveM Duvic
Dermatology, M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma 1:S15-20. 2000..New agents including bexarotene (a rexinoid) and DAB(389)IL-2 (interleukin-2 diphtheria fusion protein) offer new therapeutic options that are advantageous for treatment of mycosis fungoides in later stages...
Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithmsM Duvic
Dermatology Section, M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma 1:S51-5. 2000..With three new highly effective agents in the armamentarium for the treatment of CTCL, new combination treatment algorithms can be tested to achieve maximal benefit and quality of life for these patients...
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoidesMadeleine Duvic
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, 77030, USA
J Am Acad Dermatol 55:807-13. 2006..Progression of mycosis fungoides is associated with Th(2) cytokines produced by a clonal proliferation of epidermotropic T-helper cells...
Vorinostat in cutaneous T-cell lymphomaMadeleine Duvic
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Drugs Today (Barc) 43:585-99. 2007..Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, can have synergistic or additive effects in a variety of cancers in clinical trials...
Systemic monotherapy vs combination therapy for CTCL: rationale and future strategiesMadeleine Duvic
Department of Dermatology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncology (Williston Park) 21:33-40. 2007..These drugs, in combination with currently used therapies, may increase the number and combinations of therapies available for the treatment of this chronic condition to optimize long-lasting responses in CTCL...
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphomaMadeleine Duvic
University of Texas MD Anderson Cancer Center, Department of Dermatology, Houston, TX 77030, USA
Expert Opin Investig Drugs 16:1111-20. 2007..The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis...
Cutaneous T-cell lymphomaMadeleine Duvic
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Am Acad Dermatol 51:S43-5. 2004
Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphomaMadeleine Duvic
Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
Clin Lymphoma Myeloma 7:51-8. 2006..The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL)...
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndromeMadeleine Duvic
Department of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Clin Oncol 28:2365-72. 2010..We studied the safety and efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT) in patients with cutaneous T-cell lymphoma (CTCL)...
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphomaMadeleine Duvic
Department of Dermatology, The University of Texas M D Anderson Cancer Center, Box 1492, 1515 Holcombe Blvd, Houston, TX 77030, USA
Clin Lymphoma Myeloma 9:412-6. 2009....
Emerging new therapies for cutaneous T-cell lymphomaM Duvic
Department of Dermatology, M D Anderson Cancer Center, Houston, Texas, USA
Dermatol Clin 18:147-56. 2000..In summary, the treatment of CTCL should continue to improve and should be focused on strategies that preserve the immune function in these patients...
Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancerM Duvic
Department of Internal Medical Specialties, M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 6:3249-59. 2000..012). TIG-3 mRNA was significantly higher in normal control skin (P = 0.001), in paired adjacent skin (median, 3; P = 0.007), and in overlying epidermis (median, 3.0; P = 0.0001) than in 21 SCC specimens as a group (median, 1.5)...
Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trialsM Duvic
Section of Dermatology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Arch Dermatol 136:1461-9. 2000..To evaluate the efficacy and safety of topical alitretinoin gel (9-cis-retinoic acid [LGD1057], Panretin gel; Ligand Pharmaceuticals, Inc, San Diego, Calif) in cutaneous Kaposi sarcoma (KS)...
Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control studyChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Cancer 122:2077-84. 2008..013) in modifying risk. Together, these findings suggest that VDR polymorphisms may directly affect or modify the risk associated with known melanoma risk factors. Larger, population-based studies are needed to replicate our findings...
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progressionLi E Wang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:6532-9. 2007..To examine the role of suboptimal DNA repair capacity (DRC) for UV light-induced DNA damage in the development of nonmelanoma skin cancer (NMSC) and tumor progression...
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanomaChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 127:276-80. 2007..26; 95% CI, 1.00-1.59) genotypes, compared with the VDR-FokI FF genotype. In conclusion, genetic variants (i.e., TaqI t protective allele and FokI f risk allele) in VDR may alter risk of CM...
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanomaChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Pharmacogenet Genomics 16:253-63. 2006..In conclusion, genetic variants in the FAS and FASLG genes may contribute to the etiology of CMM in the general population, particularly in those with a low risk of sunlight-induced CMM...
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysisChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Unit 1365, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer Epidemiol Biomarkers Prev 15:2526-32. 2006..We concluded that genetic variants of the XPD gene might serve as biomarkers for susceptibility to cutaneous melanoma...
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanomaChunying Li
Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Hum Mutat 29:1443-51. 2008..Therefore, these CASP8 and CASP10 polymorphisms may be biomarkers for susceptibility to CM...
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysisLi-E Wang
Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
J Natl Cancer Inst 97:1822-31. 2005..CONCLUSIONS: UVB-induced mutagen sensitivity may play a role in susceptibility to NMSC but not to CMM...
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignanciesApostolia-Maria Tsimberidou
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 100:574-80. 2004..CONCLUSIONS: IFN-alpha and isotretinoin combination therapy had antitumor activity and was well tolerated in heavily pretreated patients with lymphoid malignancies...
Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot studyNarin Apisarnthanarax
Department of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA
J Am Acad Dermatol 50:600-7. 2004..CONCLUSION: In this small pilot study, tazarotene 0.1% gel was a well-tolerated and effective adjuvant topical for the treatment of refractory MF lesions by clinical and histologic assessments...
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanomaChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 27:1894-901. 2006..Larger studies with more SNPs in the BER genes are needed to verify these findings...
Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control studyChunying Li
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 109:1570-8. 2007..The authors hypothesized that selected functional single-nucleotide polymorphisms (SNPs) in the nNOS and iNOS genes are associated with the risk of CM...
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphomaRakhshandra Talpur
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030-4095, USA
J Invest Dermatol 126:575-83. 2006..These data suggest that high CD25 expression by IHC is associated with advanced CTCL and with clinical response to denileukin diftitox therapy...
CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexateJustin J Leitenberger
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
J Am Acad Dermatol 58:480-4. 2008..Our observation highlights pralatrexate as a promising therapeutic option for hematodermic/plasmacytoid dendritic cell lymphoma/leukemias...
4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysisLi E Wang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 127:196-205. 2007..However, there is a lack of correlation between UVB-induced b/c and 4-NQO-induced b/c in this study population. Therefore, these findings need to be verified by additional studies...
Genome-wide association study in alopecia areata implicates both innate and adaptive immunityLynn Petukhova
Department of Dermatology, Columbia University, New York, New York 10032, USA
Nature 466:113-7. 2010..We have defined the genetic underpinnings of AA, placing it within the context of shared pathways among autoimmune diseases, and implicating a novel disease mechanism, the upregulation of ULBP ligands, in triggering autoimmunity...
Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndromeJonathan L Curry
Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Cutan Pathol 38:295-7. 2011..As far as we are aware, this is the first report of an Epstein-Barr virus-associated B-cell lymphoproliferative disorder, secondary to methotrexate therapy in a patient with mycosis fungoides/Sézary syndrome...
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanomaHongbing Shen
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 121:1510-4. 2003..Further larger studies are needed to substantiate our findings...
Treatment of mycosis fungoides with denileukin diftitox and oral bexaroteneRakhshandra Talpur
Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, 77030-4095, USA
Clin Lymphoma Myeloma 6:488-92. 2006..The purpose of this case report is to show the value of sequential combination therapy for improving overall response...
Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signalingChunlei Zhang
Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 130:2110-9. 2010..Our findings provide a mechanistic rationale for the potential use of curcumin as a therapeutic agent for patients with CTCL...
Repair of UV light-induced DNA damage and risk of cutaneous malignant melanomaQingyi Wei
Department of Epidemiology, Unit 189, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
J Natl Cancer Inst 95:308-15. 2003....
The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cellsChunlei Zhang
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 123:380-7. 2004..Our findings suggest the rationale for further investigation of the clinical potential of CDDO, either alone or in combination with bexarotene for MF/SS patients...
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanomaLi E Wang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Eur J Cancer 47:107-15. 2011..56 and 2.13, 95% CIs=1.02-2.38 and 1.22-3.70, respectively). These findings suggest that MMP1 promoter polymorphisms may individually or jointly play roles in the development of CM...
The spectrum of hair loss in patients with mycosis fungoides and Sézary syndromeMing Yang Bi
Baylor College of Medicine, Houston, Texas, USA
J Am Acad Dermatol 64:53-63. 2011..Alopecia can be a manifestation of mycosis fungoides (MF) and Sézary syndrome (SS), but the prevalence is unknown...
Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphomaChunlei Zhang
Department of Dermatology, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Dermatol Ther 16:322-30. 2003..Identification of new receptor subtype-selective retinoids, combination of various receptor-selective retinoids or other agents, and a new drug delivery system may improve the clinical efficacy of retinoids in the future...
Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patientsSteve A May
Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
Am J Dermatopathol 29:62-7. 2007..These cases are strikingly similar, and may represent an unusual clinicopathologic type of T-cell lymphoma that can hone to cutaneous and oral mucosal sites with a slowly progressive natural history...
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphomaChristiane Querfeld
Department of Dermatology, Northwestern University, Chicago, IL 60611, USA
Leuk Lymphoma 52:1474-80. 2011..Enzastaurin was well tolerated with mostly grade 1-2 adverse events, mainly diarrhea and fatigue. There were two adverse event-related drug discontinuations with one possibly treatment-related...
Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cellsChunlei Zhang
Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 128:2728-35. 2008..Our findings underlie the therapeutic potential of avicin D in patients with SS...
Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoidesPutao Cen
Department of Investigational Cancer Therapeutics Phase I Program, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Am Acad Dermatol 58:382-6. 2008..29), which is expressed on most carcinoma cells, is a soluble form of the glycoprotein MUC1. Measuring CA27.29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer...
Clusterin expression correlates with stage and presence of large cells in mycosis fungoidesPranil Chandra
Department of Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 85, Houston, TX 77030, USA
Am J Clin Pathol 131:511-5. 2009..Clusterin expression was not specific for MF as it also was positive in 3 of 3 cases of LyP, 2 of 2 systemic ALCL cases involving skin, 7 of 16 cutaneous ALCLs, and 1 of 6 PTCLs...
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)Rakhshandra Talpur
Department of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston 77030-4095, USA
Leuk Lymphoma 43:121-6. 2002....
Optimizing bexarotene therapy for cutaneous T-cell lymphomaRakhshandra Talpur
Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
J Am Acad Dermatol 47:672-84. 2002..When bexarotene is combined with other active CTCL therapies, higher RRs were achieved in patients with advanced disease, without unacceptable side effects...
Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapyDan Jones
Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 10:5587-94. 2004..Using concurrent tumor samples from different anatomical sites, we compared expression of the therapeutic targets CD25 and CD30 in T-cell lymphoma (TCL)...
Efficacy and safety of topical tazarotene: a reviewRakhashandra Talpur
University of Texas, MD Anderson Cancer Center, Department of Dermatology, Houston, Texas, USA
Expert Opin Drug Metab Toxicol 5:195-210. 2009..Tazarotene (Tazorac, Avage, Allergan, Inc., Irvine, CA, USA) is a synthetic retinoic acid receptor- betagamma topical retinoid approved for the treatment of plaque psoriasis and acne vulgaris...
History of atopy or autoimmunity increases risk of alopecia areataNazila Barahmani
Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Am Acad Dermatol 61:581-91. 2009..The association between a history of atopy or autoimmune diseases and risk of alopecia areata (AA) is not well established...
Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case seriesKelley A Vidulich
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77027, USA
Int J Dermatol 48:598-602. 2009..Mycosis fungoides (MF)/Sézary syndrome (SS) patients are immunocompromised and thus may be susceptible to high-risk human papillomavirus (HPV) infections that are difficult to treat...
Poor prognosis in non-Caucasian patients with early-onset mycosis fungoidesGrace Sun
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
J Am Acad Dermatol 60:231-5. 2009..Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, is most often seen in middle-aged to elderly men...
Skin directed therapy for mycosis fungoides: a reviewCindy Berthelot
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
J Drugs Dermatol 7:655-66. 2008....
Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphomaMadeleine Duvic
Division of Internal Medicine, Department of Dermatology, University of Texas M. D. Anderson Cancer Center, Houston 77030-4095, USA
J Am Acad Dermatol 49:35-49. 2003....
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic actionChunlei Zhang
Department of Dermatology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 125:1045-52. 2005..Our data suggest that selective induction of malignant T cell apoptosis and modulation of acetylated histones, p21(WAF1), bax, Stat6, and caspase-3 may underlie the therapeutic action of SAHA in CTCL patients...
High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanomaSean D Doherty
Baylor College of Medicine, Houston, Texas, USA
Melanoma Res 16:461-3. 2006
Treatment of cutaneous T cell lymphoma: current status and future directionsNarin Apisarnthanarax
Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Am J Clin Dermatol 3:193-215. 2002..Further developments for CTCL may include more selective immunomodulatory agents, vaccines, and monoclonal antibodies...
Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomasApostolia-Maria Tsimberidou
Department of Leukemia, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA
J Am Acad Dermatol 51:200-4. 2004..CONCLUSION: This pilot study suggests that etanercept is safe and generally well tolerated in patients with CTCL. The effect of etanercept in a larger cohort of patients with early disease merits investigation...
Clonal heterogeneity in mycosis fungoides and its relationship to clinical courseFrancisco Vega
Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Blood 100:3369-73. 2002..Demonstration of identical clonal GRs in multiple biopsy specimens at the time of diagnosis may provide prognostic information related to disease progression...
Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoidesFarah Ghori
Department of Dermatology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, Texas 77030, USA
J Clin Endocrinol Metab 91:2205-8. 2006..CONCLUSIONS: Monitoring thyroid function before and during treatment with denileukin diftitox is recommended. Symptomatic thyrotoxicosis may be missed due to other acute reactions to the drug, and subsequent hypothyroidism may develop...
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1Parul Hazarika
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer Res 64:7361-9. 2004..Flot-2 binds to PAR-1, a known upstream mediator of major signal transduction pathways implicated in cell growth and metastasis, and may thereby influence tumor progression...
Cutaneous T-cell lymphoma. New immunomodulatorsN Apisarnthanarax
Division of Internal Medicine, Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
Dermatol Clin 19:737-48. 2001..It seems that further delineation of CTCL cytokine profile changes and immunologic aberrations are key in developing effective immunomodulators that are able to reverse these alterations...
DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanomaZhigang Duan
Departments of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Epidemiol Biomarkers Prev 11:1142-3. 2002
Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomasDi Lu
Department of Hematopathology, UT-M.D. Anderson Cancer Center, Houston, TX 77030, USA
J Cutan Pathol 29:465-72. 2002....
Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitoxKelley Vidulich
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Clin Lymphoma Myeloma 8:55-8. 2008..We describe a patient with deep ulcers initially diagnosed as pyoderma gangrenosum, which was reclassified as CGD-TCL. Local radiation followed by weekly infusions of denileukin diftitox put the patient into remission...
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center seriesApostolia-Maria Tsimberidou
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Cancer 100:342-9. 2004..A transient early "flare" of disease was observed in some responders. CONCLUSIONS: At these doses, pentostatin was reasonably well tolerated and is an effective drug for the treatment of T-cell lymphomas...
Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapyCindy Berthelot
University of Texas Medical School Southwestern, Dallas, 77030, USA
Clin Lymphoma Myeloma 6:329-32. 2006..Herein, we describe 2 patients who developed unusual CD8+ cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed...
Current treatment of Cutaneous T-Cell LymphomaM Duvic
University of Texas, MD Anderson Cancer Center, USA
Dermatol Online J 7:3. 2001..In the United States, the incidence of these diseases is rising faster than any other cancer. Environmental triggers may be important in the evolution of malignancy. Current therapy is reviewed with emphasis on a new retinoid, Targretin...
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytesNam H Dang
MD Anderson Cancer Center, Houston, TX 77030, USA
Oncol Rep 10:1513-8. 2003..We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications...
Mortality risk from squamous cell skin cancerGary L Clayman
Department of Head and Neck Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 23:759-65. 2005..To identify nonmelanoma skin cancer patients with squamous cell carcinoma (SCC) who are at greatest risk of disease-specific mortality...
Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowelAshley G Perna
Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Clin Lymphoma 5:190-3. 2004..However, the LyP relapsed and proved refractory to psoralen plus ultraviolet-A phototherapy, and was only temporarily and partially responsive to bexarotene and denileukin diftitox...
Coexistent psoriasis and lupus erythematosus treated with alefaceptCindy Berthelot
Department of Internal Medicine, University of Texas Houston Health Science Center, Houston, TX, USA
Am J Clin Dermatol 8:47-50. 2007..The patient's arthritis flared after the second infusion of infliximab, which was discontinued. During treatment with alefacept, the patient's psoriasis improved markedly without exacerbation of his photosensitive SCLE lesions...
The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task ForceTimothy G Berger
Department of Dermatology, University of California, San Francisco, California, USA
J Am Acad Dermatol 54:818-23. 2006
Multiple plaques on the hands and feet. Mycosis fungoides (MF) palmaris et plantaris (MFPP)Thomas J Lambert
Texas Tech University School of Medicine, Lubbock, TX, USA
Arch Dermatol 143:109-14. 2007
Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformisJenny Vu
Department of Dermatology, University of Texas MD Anderson Cancer Center and Medical School, Houston, Texas 77030 4009, USA
Am J Clin Dermatol 8:307-10. 2007..Our case is the second reported case of common variable immunodeficiency syndrome associated with EV...
Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphomaKristel Polder
Memorial Hermann Hospital, University of Texas Health Science Center at Houston, TX, USA
Leuk Lymphoma 46:1807-11. 2005..The clinical features and pathology were compatible with toxic epidermal necrolysis. This is the first reported case of toxic epidermal necrolysis in the literature associated with denileukin diftitox...
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndromeDaniel J Lenihan
Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, USA
Blood 104:655-8. 2004..The role of this agent in potentially inducing important cardiac side effects is suggested and argues for further investigation...
Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNAXiao Ni
Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Invest Dermatol 128:2631-9. 2008..These data support the concept of using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific antigens in patients with SzS...
Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndromeR Talpur
Division of Internal Medicine, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Br J Dermatol 159:105-12. 2008..Superantigens from Staphylococcus aureus can stimulate T cells...
Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopyN Barahmani
Department of Dermatology, University of Texas M D Anderson Center, Houston, TX 77030, USA
Clin Exp Dermatol 35:409-16. 2010..The role of T helper (Th)1 and Th2 cytokines in the pathogenesis of AA have not been established...
Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapyA H Sarris
Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 19:398-405. 2001..Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL)...
Dendritic cells and cutaneous T-cell lymphomasX Ni
Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
G Ital Dermatol Venereol 146:103-13. 2011..Further understanding of DCs and their role in CTCLs can help us to uncover the pathogenesis of this disease and to further explore the therapeutic uses of DCs...
Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphomaM Duvic
M D Anderson Cancer Center, Houston, TX 77030, USA
Arch Dermatol 137:581-93. 2001..To determine the safety and efficacy of oral bexarotene (Targretin capsules; Ligand Pharmaceuticals Incorporated, San Diego, Calif)...
Central hypothyroidism associated with retinoid X receptor-selective ligandsS I Sherman
Section of Endocrine Neoplasia and Hormonal Disorders, University of Texas M D Anderson Cancer Center, Houston 77030, USA
N Engl J Med 340:1075-9. 1999....
Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatmentJ A Pielop
Baylor College of Medicine, Houston, Texas, USA
Int J Dermatol 40:505-11. 2001....
Molecular mechanisms of tazarotene action in psoriasisM Duvic
Department of Dermatology, University of Texas Medical School, Houston 77030, USA
J Am Acad Dermatol 37:S18-24. 1997..The effect of tazarotene on these markers is probably a direct effect on gene expression rather than an indirect effect associated with disease improvement...
Therapy options in cutaneous T-cell lymphomaN Apisarnthanarax
Department of Dermatology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 434, Houston, TX 77030-4095, USA
Expert Rev Anticancer Ther 1:403-20. 2001..This article will present and discuss the optimal therapeutic agents for all clinical stages of CTCL patients, based on currently available and investigational agents...
Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial resultsM Duvic
M.D. Anderson Cancer Center, Houston, TX
J Clin Oncol 19:2456-71. 2001..Bexarotene is orally administered, safe, and generally well tolerated with reversible side effects, and is effective for the treatment of advanced, refractory CTCL...
HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphomaC M Jackow
Department of Dermatology, University of Texas Medical School, Houston 77030, USA
J Invest Dermatol 107:373-6. 1996..These data suggest that certain HLA-DRB and DQB1 alleles, also associated with other T-cell-mediated skin diseases, may participate in the pathogenesis of or susceptibility to CTCL...
Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides?C M Jackow
Department of Dermatology, University of Texas Medical School, Houston 77030, USA
J Am Acad Dermatol 37:828-31. 1997..Epidermotropic T-cell skin diseases with oligoclonal T-cell proliferations may be the result of HLA- and cytokine-determined reaction patterns to persistent antigens...
Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?X Ni
Department of Dermatology, University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 7:2682-92. 2001..01 +/- 0.86%) compared with non-FasL expressing areas (13.53 +/- 3.54%; P < 0.02). These results suggest that a potential mechanism of tumor immune escape in MF is FasL-mediated apoptosis of infiltrating CD8+ CTLs...
Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral bloodD Jones
Division of Pathology and Laboratory Medicine, University of Texas-M.D. Anderson Cancer Center, Houston, USA
Am J Clin Pathol 115:885-92. 2001....
Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formationP Hazarika
Department of Dermatology, University of Texas Medical School and Department of Medical Specialties, Section of Dermatology, MD Anderson Cancer Center, Houston, Texas 77030, USA
J Cell Biochem 75:147-59. 1999..Thus, the function of flotillin 2 may resemble that of the goldfish optic nerve neuronal regeneration proteins, Reggie 1 and 2...
Research Grants
- CUTANEOUS ONCOLOGYMadeleine Duvic; Fiscal Year: 2004This is a mid-career development award application for Madeleine Duvic, Professor of Medicine and Chief of Dermatology at the MD Anderson Cancer Center...
